Japan to set price of SMA drug Zolgensma at 167 million Yen

Nippon

12 May 2020 - Japan's health ministry is planning to set the price of Novartis AG's spinal muscular atrophy drug Zolgensma at about 167 million yen, or some 1.55 million dollars, under the country's health insurance system, informed sources said Tuesday.

Zolgensma will be the most expensive drug covered by health insurance in Japan. 

Insurance coverage for the drug is expected to be approved at a general meeting of the Central Social Insurance Medical Council, an advisory panel to the health minister, on Wednesday.

Read Nippon article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Pricing , Gene therapy , Japan